The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">acute_2</font> <font color="red">myeloid_2</font> <font color="red">leukemia_2</font> <font color="red">and_2</font> <font color="red">myelodysplastic_2</font> <font color="red">syndromes_2</font> <font color="red">:_2</font> a Japanese multicenter randomized , controlled study . 
<br>
<br> We performed a randomized , controlled study comparing the prophylactic effects of capsule forms of fluconazole ( n = 110 ) and itraconazole ( n = 108 ) in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">acute_2</font> <font color="red">myeloid_2</font> <font color="red">leukemia_2</font> <font color="red">(_2</font> <font color="red">AML_2</font> <font color="red">)_2</font> <font color="red">or_2</font> <font color="red">myelodysplastic_2</font> <font color="red">syndromes_2</font> <font color="red">(_2</font> <font color="red">MDS_2</font> <font color="red">)_2</font> <font color="red">during_2</font> <font color="red">and_2</font> <font color="red">after_2</font> <font color="red">chemotherapy_2</font> <font color="red">._2</font> There were 4 cases with possible systemic fungal infection in the itraconazole group , and there were 8 possible and 3 probable cases in the fluconazole group . Adverse events did not significantly differ in the 2 groups . In <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">MDS_1</font> <font color="red">or_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">remission_1</font> <font color="red">-_1</font> <font color="red">induction_1</font> <font color="red">phase_1</font> <font color="red">of_1</font> <font color="red">chemotherapy_1</font> <font color="red">,_1</font> the numbers of cases with probable or possible infections were lower in the itraconazole group than in the fluconazole group , whereas no difference was seen in patients with AML or in the consolidation phase of therapy . In <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">neutrophil_1</font> <font color="red">counts_1</font> <font color="red">of_1</font> <font color="red">>_1</font> <font color="red">0.1_1</font> <font color="red">x_1</font> <font color="red">10(9)/L_1</font> <font color="red">lasting_1</font> <font color="red">for_1</font> <font color="red">more_1</font> <font color="red">than_1</font> <font color="red">4_1</font> <font color="red">weeks_1</font> <font color="red">,_1</font> the frequency of infection in the fluconazole group ( 5 of 9 patients ) was significantly higher than in the itraconazole group ( 0 of 7 patients ; P = .03 ) . Our results suggest that both drugs were well tolerated in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">AML_2</font> <font color="red">or_2</font> <font color="red">MDS_2</font> <font color="red">who_2</font> <font color="red">received_2</font> <font color="red">chemotherapy_2</font> and that the efficacy of itraconazole for prophylaxis against systemic fungal disease is not inferior to that of fluconazole .